Please assess the completion status of the following clinical trial:

Trial Title: Clofarabine Pre-conditioning Followed by Stem Cell Transplant for Non-remission AML

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnostic criteria of AML, induction failure without having achieved remission after at least 2 attempts at induction chemotherapy, or relapsed after any complete remission (CR).~2. 18 to 75 years of age.~3. Planned or scheduled to receive an allogeneic HSCT from haploidentical related donors, matched and mismatched unrelated donors.~4. All organ function testing should be done within 28 days of study registration.~   * Performance status: Karnofsky ≥ 70% (Appendix A).~  * Cardiac: LVEF ≥ 50% by MUGA or echocardiogram.~  * Pulmonary: FEV1 and FVC ≥ 50% predicted, DLCO (corrected for hemoglobin) ≥ 50% of predicted.~  * Renal: Creatinine clearance (CrCl) ≥ 60 mL/min/1.73 m2~  * Hepatic: Serum bilirubin ≤1.5 x upper limit of normal (ULN); (AST)/(ALT) ≤ 2.5 x ULN; Alkaline phosphatase ≤ 2.5 x ULN.~5. Both men and women need to use an approved method of birth control and/or abstinence due to unknown risks to the fetus.~Exclusion Criteria:~1. Acute promyelocytic leukemia (APL)~2. Known history of non-compliance with medication regimens, scheduled clinic visits, or self-care.~3. In the opinion of the investigator, no appropriate caregivers identified.~4. HIV1 (Human Immunodeficiency Virus-1) or HIV2 positive~5. Active Hepatitis B and Hepatitis C orepatitis positive serology including HBsAg, hepatitis B core antibody, and hepatitis C antibody. Hepatitis B surface antibody positive due to vaccination or natural immunity are permitted.~6. In the opinion of the physician investigator, uncontrolled medical or psychiatric disorders.~7. Uncontrolled infections requiring treatment within 14 days of registration.~8. Active central nervous system (CNS) leukemia.~9. Cord blood transplant excluded.~10. Prior allogeneic HSCT within last 6 months.~11. Patients with \>= grade 2 acute GVHD.~12. Patients with \>=moderate chronic GVHD.~13. Pregnant or Breastfeeding. Women of child bearing potential (WCBP) are required to have a negative serum or urine pregnancy test prior to initiation of conditioning regimen.~14. Haploidentical related donors who are positive for DSA ≥ 5000 MFI by solid phase microarray method (Luminex).~15. Any patient with steroid dose more than 10 mg/day within a week of registration .~16. Autoimmune disorder requiring any active immunosuppression therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Clofarabine 30 mg/m^2 (Type: EXPERIMENTAL): Day -14 through Day -10 Clofarabine 30 mg/m\^2, Day - 9 Day of rest, Day - 8 Day of rest, Day - 7 Day of rest, Day - 6 Fludarabine 40 mg/m\^2 IV and Busulfan 3.2 mg/kg IV (Regimen A, Fludarabine 24 mg/m\^2 IV and Cyclophosphamide 14.5 mg/kg IV for Regimen B), Day - 5 Fludarabine 40 mg/m\^2 IV and Busulfan 3.2 mg/kg IV (Regimen A, Fludarabine 24 mg/m\^2 IV and Cyclophosphamide 14.5 mg/kg IV for Regimen B), Day - 4 Fludarabine 40 mg/m\^2 IV(Regimen A, Fludarabine 24 mg/m\^2 IV for Regimen B), Day - 3 Fludarabine 40 mg/m\^2 IV(Regimen A, Fludarabine 24 mg/m\^2 IV for Regimen B), Day - 2 Day of Rest, Day -1 Total Body Irradiation 200 cGys, Day 0 stem cell transplant infusion, Day +1 Day of rest, Day +2 Day of rest, Day +3 Cyclophosphamide 50 mg/kg IV, Day +4 Cyclophosphamide 50 mg/kg IV, Day +5 Start G-CSF, Tacrolimus, and MMF.

Based on this trial design, predict the completion outcome and termination type (if applicable).